Fludarabine
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rapamycin OHSU Knight Cancer Institute | Phase 2 | B |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | B |
TACROLIMUS Fred Hutchinson Cancer Center | Phase 2 | B |
Carboplatin OHSU Knight Cancer Institute | Phase 2 | B |
Ruxolitinib St. Petersburg State Pavlov Medical University | Phase 2 | B |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →